Surmodics (SRDX) Competitors $27.39 -0.11 (-0.40%) As of 01:28 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SRDX vs. IART, OFIX, ANGO, ARAY, RMTI, ABT, ISRG, BSX, SYK, and MDTShould you be buying Surmodics stock or one of its competitors? The main competitors of Surmodics include Integra LifeSciences (IART), Orthofix Medical (OFIX), AngioDynamics (ANGO), Accuray (ARAY), Rockwell Medical (RMTI), Abbott Laboratories (ABT), Intuitive Surgical (ISRG), Boston Scientific (BSX), Stryker (SYK), and Medtronic (MDT). These companies are all part of the "health care equipment" industry. Surmodics vs. Its Competitors Integra LifeSciences Orthofix Medical AngioDynamics Accuray Rockwell Medical Abbott Laboratories Intuitive Surgical Boston Scientific Stryker Medtronic Surmodics (NASDAQ:SRDX) and Integra LifeSciences (NASDAQ:IART) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership. Do insiders & institutionals hold more shares of SRDX or IART? 96.6% of Surmodics shares are owned by institutional investors. Comparatively, 84.8% of Integra LifeSciences shares are owned by institutional investors. 8.9% of Surmodics shares are owned by insiders. Comparatively, 3.5% of Integra LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts prefer SRDX or IART? Surmodics currently has a consensus target price of $43.00, indicating a potential upside of 56.99%. Integra LifeSciences has a consensus target price of $16.17, indicating a potential upside of 0.26%. Given Surmodics' stronger consensus rating and higher possible upside, research analysts plainly believe Surmodics is more favorable than Integra LifeSciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Surmodics 1 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Integra LifeSciences 4 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 1.75 Which has preferable valuation and earnings, SRDX or IART? Integra LifeSciences has higher revenue and earnings than Surmodics. Surmodics is trading at a lower price-to-earnings ratio than Integra LifeSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSurmodics$126.08M3.11-$11.54M-$1.23-22.27Integra LifeSciences$1.61B0.78-$6.94M-$6.53-2.47 Is SRDX or IART more profitable? Surmodics has a net margin of -14.59% compared to Integra LifeSciences' net margin of -30.87%. Integra LifeSciences' return on equity of 12.15% beat Surmodics' return on equity.Company Net Margins Return on Equity Return on Assets Surmodics-14.59% -2.99% -1.99% Integra LifeSciences -30.87%12.15%4.32% Which has more volatility and risk, SRDX or IART? Surmodics has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500. Comparatively, Integra LifeSciences has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500. Does the media prefer SRDX or IART? In the previous week, Integra LifeSciences had 2 more articles in the media than Surmodics. MarketBeat recorded 2 mentions for Integra LifeSciences and 0 mentions for Surmodics. Integra LifeSciences' average media sentiment score of 0.20 beat Surmodics' score of 0.00 indicating that Integra LifeSciences is being referred to more favorably in the news media. Company Overall Sentiment Surmodics Neutral Integra LifeSciences Neutral SummarySurmodics and Integra LifeSciences tied by winning 8 of the 16 factors compared between the two stocks. Get Surmodics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRDX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SRDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SRDX vs. The Competition Export to ExcelMetricSurmodicsMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$391.18M$10.74B$6.17B$10.79BDividend YieldN/A1.87%5.72%4.83%P/E Ratio-22.2421.2429.8628.66Price / Sales3.1131.36502.16190.02Price / Cash91.4124.6936.5560.64Price / Book3.293.4812.046.62Net Income-$11.54M$210.63M$3.33B$276.93M7 Day Performance-2.14%0.40%1.59%2.04%1 Month Performance-10.08%0.20%6.23%2.66%1 Year Performance-28.17%-7.69%61.20%33.98% Surmodics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SRDXSurmodics3.6453 of 5 stars$27.39-0.4%$43.00+57.0%-28.2%$391.18M$126.08M-22.24450IARTIntegra LifeSciences2.5646 of 5 stars$13.62+2.1%$16.83+23.6%-16.9%$1.04B$1.61B-2.094,396Upcoming EarningsOFIXOrthofix Medical2.3757 of 5 stars$14.50+2.1%$21.75+50.0%+1.6%$560.82M$799.49M-4.571,616News CoverageAnalyst ForecastANGOAngioDynamics4.4976 of 5 stars$11.13+1.2%$19.33+73.7%+68.1%$453.20M$292.50M-14.27760Positive NewsAnalyst ForecastInsider TradeARAYAccuray4.221 of 5 stars$1.76-0.6%$5.00+184.1%-9.1%$199.51M$458.51M-88.001,040Analyst ForecastGap UpRMTIRockwell Medical3.692 of 5 stars$1.14+3.6%$4.00+250.9%-67.0%$37.87M$101.49M-19.00300ABTAbbott Laboratories4.9793 of 5 stars$131.52-0.8%$146.17+11.1%+8.1%$230.73B$41.95B16.48114,000Positive NewsAnalyst ForecastISRGIntuitive Surgical4.6095 of 5 stars$435.73+1.4%$584.76+34.2%+7.6%$154.00B$8.35B60.7715,638Trending NewsEarnings ReportAnalyst ForecastOptions VolumeBSXBoston Scientific4.7951 of 5 stars$94.92-0.5%$120.71+27.2%+17.1%$141.37B$16.75B56.5053,000Trending NewsEarnings ReportAnalyst ForecastOptions VolumeAnalyst RevisionSYKStryker4.8319 of 5 stars$364.95+0.1%$432.14+18.4%+5.6%$139.39B$22.60B48.3453,000Positive NewsUpcoming EarningsAnalyst ForecastMDTMedtronic4.95 of 5 stars$95.63+0.2%$102.41+7.1%+2.1%$122.43B$33.54B26.3495,000Positive NewsOptions Volume Related Companies and Tools Related Companies Integra LifeSciences Competitors Orthofix Medical Competitors AngioDynamics Competitors Accuray Competitors Rockwell Medical Competitors Abbott Laboratories Competitors Intuitive Surgical Competitors Boston Scientific Competitors Stryker Competitors Medtronic Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SRDX) was last updated on 10/24/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredMy starkest warning in years Porter Stansberry — founder of one of the world’s largest financial research firms — believes we’re entering a...Porter & Company | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Surmodics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Surmodics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
